Evaluation of the efficacy of triazavirin versus oseltamivir in management of COVID-19.

To compare the safety and efficacy of triazavirin (TZV) 250 mg capsules versus oseltamivir 75 mg capsules in the treatment of individuals diagnosed with COVID-19. A double-blind, randomized, interventional pilot study was conducted in a parallel design with a 7-day treatment period. The results showed that TZV is superior to oseltamivir regarding length of hospital stay, days until clinical symptoms improvement, and cure of chest pneumonia.